The current status and progress of ocriplasmin in treating vitreomacular interface diseases
10.3760/cma.j.issn.1005-1015.2017.02.025
- VernacularTitle:奥克纤溶酶治疗玻璃体黄斑界面疾病研究现状与进展
- Author:
Jiamin XIE
;
Xun XU
- Keywords:
Retinal perforations/drug therapy;
Fibrinolysin/therapeutic use;
Vitreomacular traction syndrome/drug therapy;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2017;33(2):203-206
- CountryChina
- Language:Chinese
-
Abstract:
As a potent collagenase activator,ocriplasmin is a recombinant truncated form of serine protease that retains the protease activity of plasmin.Pre-clinical animal experiments,clinical trials and recent clinical studies all indicated a promising outcome of intravitreal injection of ocriplasmin to treat vitreomacular interface diseases,including vitreomacular adhesion (VMA),vitreomacular traction (VMT) and full-thickness macular hole.Ocriplasmin was approved by the Food and Drug Administration of USA in the management of symptomatic VMA,and by the European Medicines Agency in treating VMT-associated macular hole with less than or equal 400 pm.Further randomized controlled clinical trials are needed for further comprehensive observation and evaluation on its efficiency,safety and other noteworthy issues.
